Live feed06:00:00·93dPRReleasevia QuantisnowAscletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for AcneByQuantisnow·Wall Street's wire, on your screen.SGMT· Sagimet Biosciences Inc.Health Care
